+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Infliximab"

Psoriasis Treatment Market Report and Forecast 2024-2032 - Product Thumbnail Image

Psoriasis Treatment Market Report and Forecast 2024-2032

  • Report
  • July 2024
  • 200 Pages
  • Global
From
From
Biosimilar Monoclonal Antibodies Market Report 2022-2032 - Product Thumbnail Image

Biosimilar Monoclonal Antibodies Market Report 2022-2032

  • Report
  • July 2022
  • 461 Pages
  • Global
From
From
From
From
Crohns Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Crohns Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 100 Pages
  • Global
From
REMICADE Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

REMICADE Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
From
From
Infliximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Infliximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
From
Infliximab Drug Market - Global Forecast Report 2023-2031 - Product Thumbnail Image

Infliximab Drug Market - Global Forecast Report 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
From
Loading Indicator

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients. Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms. The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more